Mays Jawad
Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia
Jawad, Mays; Yu, Ning; Seedhouse, Claire; Tandon, Karuna; Russell, Nigel H; Pallis, Monica
Authors
Ning Yu
CLAIRE SEEDHOUSE CLAIRE.SEEDHOUSE@NOTTINGHAM.AC.UK
Associate Professor
Karuna Tandon
Nigel H Russell
Monica Pallis
Abstract
Background
The CD34+CD38- subset of AML cells is enriched for resistance to current chemotherapeutic agents and considered to contribute to disease progression and relapse in Acute Myeloid Leukaemia (AML) patients following initial treatment.
Methods
Chemosensitivity in phenotypically defined subsets from 34 primary AML samples was measured by flow cytometry following 48 hr in vitro treatment with gemtuzumab ozogamicin (GO, Mylotarg) and the farnesyltransferase inhibitor tipifarnib/zarnestra. The DNA damage response was measured using flow cytometry, immunofluorescence and immunohistochemistry.
Results
Using a previously validated in vitro minimal residual disease model, we now show that the combination of GO (10 ng/ml) and tipifarnib (5 μM) targets the CD34+CD38- subset resulting in 65% median cell loss compared to 28% and 13% CD34+CD38- cell loss in GO-treated and tipifarnib-treated cells, respectively. Using phosphokinome profiling and immunofluorescence in the TF-1a cell line, we demonstrate that the drug combination is characterised by the activation of a DNA damage response (induction of γH2A.X and thr68 phosphorylation of chk2). Higher induction of γH2AX was found in CD34+CD38- than in CD34+CD38+ patient cells. In a model system, we show that dormancy impairs damage resolution, allowing accumulation of γH2AX foci.
Conclusions
The chemosensitivity of the CD34+CD38- subset, combined with enhanced damage indicators, suggest that this subset is primed to favour programmed cell death as opposed to repairing damage. This interaction between tipifarnib and GO suggests a potential role in the treatment of AML.
Citation
Jawad, M., Yu, N., Seedhouse, C., Tandon, K., Russell, N. H., & Pallis, M. (2012). Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia. BMC Cancer, https://doi.org/10.1186/1471-2407-12-431
Journal Article Type | Article |
---|---|
Acceptance Date | Sep 21, 2012 |
Online Publication Date | Sep 26, 2012 |
Publication Date | 2012 |
Deposit Date | Apr 5, 2024 |
Publicly Available Date | May 3, 2024 |
Journal | BMC Cancer |
Electronic ISSN | 1471-2407 |
Publisher | Springer Verlag |
Peer Reviewed | Peer Reviewed |
DOI | https://doi.org/10.1186/1471-2407-12-431 |
Public URL | https://nottingham-repository.worktribe.com/output/32755012 |
Publisher URL | https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-431 |
Files
1471-2407-12-431
(1.2 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/2.0/
You might also like
Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
(2023)
Journal Article
Direct RT-qPCR Assay for the Detection of SARS-CoV-2 in Saliva Samples
(2022)
Journal Article
Saliva for COVID-19 testing: Simple but useless or an undervalued resource?
(2021)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search